Nanocapsule nerve growth factor for ALS
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This trial is testing a new way to deliver nerve growth factor using tiny, protective nanocapsules injected into the body. The goal is to see if this treatment can slow the progression of ALS (Lou Gehrig's disease) and help maintain muscle strength and breathing function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a diagnosis of ALS (either definite or possible) for at least 6 months but no more than 3 years.
- Your breathing strength (FVC) is at least 85% of what is expected for your age, height, and gender.
- You do not use a breathing machine or have a tracheostomy tube.
- You are not taking blood thinners and do not have a bleeding disorder.
- You do not have any other serious medical conditions like severe heart failure, active infections, or psychiatric disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment aimed at restoring the function of a gene called UNC13A in people with ALS. It involves multiple clinic visits, MRI scans, and spinal taps to see if the treatment is safe and may slow the disease.
This trial tests whether injecting neural stem cells into the spine can slow down ALS. It is for people with rapidly progressing ALS who have good lung function and a caregiver to help with visits.
This trial tests whether adding two supplements (EH-301 and N-acetylcysteine) to the standard ALS medicine Riluzole can help slow the disease. It is for people diagnosed with ALS within the last 18 months who still have good breathing and daily function.
This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.
This trial tests a single injection of a gene therapy called INS1202 into the spinal fluid. It is for people with ALS, including those with a specific genetic form (SOD1 mutation). The goal is to see if it is safe and how it affects the body.
This trial tests an experimental drug called MRG-001 for people with amyotrophic lateral sclerosis (ALS). It aims to see if the drug can help slow the progression of the disease.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.